For other conditions, JAK-inhibitors have been used in a small number of patients with good outcomes, including STING-associated vasculopathy with onset in infancy, Aicardi-Goutières syndrome (AGS) and mutations interfering with IFN signaling (137). The gene discussed is STING1; the disease is Aicardi-Goutieres syndrome.